| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Pentafluorobenzenesulfonyl fluorescein does not have a specific biological target as a drug; it is a fluorescent probe. The fluorescein moiety provides fluorescence properties (excitation ~494 nm, emission ~521 nm) that enable detection, while the pentafluorobenzenesulfonyl group allows for conjugation to amine or thiol groups on proteins and other biomolecules. The compound is used to label and track biological molecules in research applications.
|
|---|---|
| ln Vitro |
Pentafluorobenzenesulfonyl fluorescein is not evaluated for biological activity as a drug; it is a fluorescent probe. Its utility is assessed by its fluorescence properties, photostability, and ability to conjugate to target molecules. The compound is used in fluorescence-based assays for protein labeling, enzyme activity, and cellular imaging.
|
| ln Vivo |
Pentafluorobenzenesulfonyl fluorescein is not evaluated for in vivo biological activity as a drug; it is a fluorescent probe. It may be used in vivo for imaging applications, such as tracking labeled proteins or cells in animal models. However, the compound itself is not a therapeutic agent.
|
| Enzyme Assay |
There are no specific in vitro enzyme or receptor binding assays for Pentafluorobenzenesulfonyl fluorescein as a drug target. As a fluorescent probe, its properties are characterized by absorbance and fluorescence spectra, quantum yield, and reactivity with nucleophiles. The compound's ability to conjugate to proteins can be assessed by SDS-PAGE and fluorescence imaging.
|
| Cell Assay |
There are no specific in vitro cellular assays for Pentafluorobenzenesulfonyl fluorescein as a pharmacologically active compound. As a fluorescent probe, it can be used to label proteins or other biomolecules for cellular imaging. Cells are incubated with the labeled molecule, and fluorescence is visualized by microscopy or flow cytometry.
|
| Animal Protocol |
There are no specific in vivo animal studies for Pentafluorobenzenesulfonyl fluorescein as a pharmacologically active compound. As a fluorescent probe, it may be used for in vivo imaging studies, where the labeled molecule is administered to animals and its distribution is tracked by fluorescence imaging.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Pentafluorobenzenesulfonyl fluorescein are not applicable, as it is a fluorescent probe rather than a drug. The compound is not intended for administration as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Pentafluorobenzenesulfonyl fluorescein is not extensively reported. As a fluorescent probe, it is not intended for human therapeutic use. The compound should be handled with care in a laboratory setting. No specific toxicity data are reported.
|
| Additional Infomation |
Pentafluorobenzenesulfonyl fluorescein (CAS 728912-45-6) is a fluorescent probe used in biochemical research for labeling and detection applications. It is a derivative of fluorescein with a pentafluorobenzenesulfonyl group for conjugation to target molecules. The compound is used in fluorescence-based assays, including protein labeling, enzyme activity assays, and cellular imaging. It is available for research purposes only.
|
| Molecular Formula |
C26H11O7F5S
|
|---|---|
| Molecular Weight |
562.41834
|
| Exact Mass |
562.014
|
| CAS # |
728912-45-6
|
| PubChem CID |
16760506
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
707.3±60.0 °C at 760 mmHg
|
| Flash Point |
381.6±32.9 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.702
|
| LogP |
5.08
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
39
|
| Complexity |
1040
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)OS(=O)(=O)C6=C(C(=C(C(=C6F)F)F)F)F
|
| InChi Key |
UIBLLPHZQUTIBL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H11F5O7S/c27-19-20(28)22(30)24(23(31)21(19)29)39(34,35)38-12-6-8-16-18(10-12)36-17-9-11(32)5-7-15(17)26(16)14-4-2-1-3-13(14)25(33)37-26/h1-10,32H
|
| Chemical Name |
(6'-hydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) 2,3,4,5,6-pentafluorobenzenesulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7780 mL | 8.8902 mL | 17.7803 mL | |
| 5 mM | 0.3556 mL | 1.7780 mL | 3.5561 mL | |
| 10 mM | 0.1778 mL | 0.8890 mL | 1.7780 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
